Metabolic Bone Diseases
Which of the following is used in osteoporosis for decreasing bone resorption and increasing bone formation.
a. Teriparatide is the portion of human parathyroid hormone (PTH),
b. Teriparatide is the first FDA approved agent for the treatment of osteoporosis that stimulates new bone formation.
c. Strontium ranelate has been shown to decrease the risk of fractures in postmenopausal women. Its efficacy in clinical studies results from its unique mode of action, on both bone resorption and bone formation. resulting in increased bone mass